Unity Biotechnology, Inc. (0YC0.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
285 East Grand Avenue
South San Francisco, CA 94080
United States of America (the)
Phone
650 416 1192
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
16
First IPO Date
October 04, 2018
| Name | Title | Pay | Year Born |
| Anirvan Ghosh | Chief Executive Officer & Director | 953,706 | 1965 |
| Nathaniel E. David | Co-Founder & Independent Director | 49,500 | 1968 |
| Alexander Hieu Nguyen | Chief Legal Officer & Head of Operations | 622,968 | 1978 |
| Federico Grossi | Chief Medical Officer | 635,790 | 1974 |
| Lynne Marie Sullivan | Chief Financial Officer & Head of Corporate Development | 679,956 | 1966 |
| Jan van Deursen | Founder | 0 | N/A |
| Przemyslaw Sapieha | Chief Scientist | 0 | N/A |
| Alicia Tozier | Chief Strategy Officer | 0 | N/A |
Unity Biotechnology, Inc. is a biotechnology firm dedicated to discovering and advancing therapies designed to slow, halt, or even reverse the progression of diseases associated with aging. The company's primary therapeutic candidate, UBX1325, is currently undergoing Phase II clinical trials, addressing age-related ocular conditions such as diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Its pipeline also features UBX1967, intended for various ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody targeting age-related vision impairments; and UBX2089, an a-Klotho hormone candidate with potential in diverse neurological applications. Originally incorporated in 2009 as Forge, Inc., the company adopted its current name, Unity Biotechnology, Inc., in January 2015 and operates from its headquarters in South San Francisco, California.